You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 20, 2025

Investigational Drug Information for Tetrahydrocannabivarin


✉ Email this page to a colleague

« Back to Dashboard


What is the drug development status for Tetrahydrocannabivarin?

Tetrahydrocannabivarin is an investigational drug.

There have been 4 clinical trials for Tetrahydrocannabivarin. The most recent clinical trial was a Phase 2 trial, which was initiated on February 1st 2014.

The most common disease conditions in clinical trials are Diabetes Mellitus, Type 2, Diabetes Mellitus, and Alopecia. The leading clinical trial sponsors are GW Research Ltd, Gregory L Smith, MD, MPH, and Medical Life Care Planners, LLC.

Recent Clinical Trials for Tetrahydrocannabivarin
TitleSponsorPhase
Weight Loss, Blood Sugar and Blood Lipid Effects of Tetrahydrocannabivarin (THCV) Impregnated Mucoadhesive StripsMedical Life Care Planners, LLCEarly Phase 1
Androgenetic Alopecia Treatment Using Varin and Cannabidiol Rich Topical Hemp Oil: A Case SeriesGregory L Smith, MD, MPHEarly Phase 1
A Study of GWP42004 as Add on to Metformin in the Treatment of Participants With Type 2 DiabetesGW Research LtdPhase 2

See all Tetrahydrocannabivarin clinical trials

Clinical Trial Summary for Tetrahydrocannabivarin

Top disease conditions for Tetrahydrocannabivarin
trials000111112222Diabetes Mellitus, Type 2Diabetes MellitusAlopeciaWeight Loss[disabled in preview]
Top clinical trial sponsors for Tetrahydrocannabivarin
trials000111112222GW Research LtdGregory L Smith, MD, MPHMedical Life Care Planners, LLC[disabled in preview]

See all Tetrahydrocannabivarin clinical trials

Tetrahydrocannabivarin (THCV): Development Updates and Market Projections

Introduction to Tetrahydrocannabivarin (THCV)

Tetrahydrocannabivarin (THCV) is a minor cannabinoid that has garnered significant attention in recent years due to its diverse therapeutic potential. Initially developed by GW Pharmaceuticals Ltd., THCV is known for its unique mechanism of action as a CB1 and CB2 receptor antagonist.

Mechanism of Action

THCV operates by antagonizing the cannabinoid CB1 and CB2 receptors. This mechanism is distinct from other cannabinoids like THC, which acts as an agonist to these receptors. The antagonistic action of THCV makes it a promising candidate for treating various conditions without the psychoactive effects associated with THC[1].

Therapeutic Areas and Indications

THCV is being explored for its therapeutic benefits in several areas, including:

Metabolic Disorders

THCV has shown potential in managing metabolic disorders such as obesity and type 2 diabetes. Its ability to modulate the endocannabinoid system can help in regulating glucose and lipid metabolism[2].

Neurological Disorders

The compound is being investigated for its efficacy in treating neurological disorders like epilepsy, Alzheimer’s disease, and Parkinson’s disease. Its neuroprotective properties make it a viable option for managing these conditions[2].

Pain Management

THCV is also being studied for its role in pain management, particularly for conditions like arthritis and neuropathic pain. Its anti-inflammatory and analgesic properties could provide relief without the side effects of traditional pain medications[2].

Other Indications

Additionally, THCV is being researched for its potential in treating immune system disorders, such as rheumatoid arthritis and inflammatory bowel disease, as well as its possible anti-cancer and mental health benefits[3].

Current Development Status

As of the latest updates, THCV is in various stages of clinical development:

Clinical Trials

Several clinical trials are ongoing to evaluate the safety and efficacy of THCV. While specific details on the current phase of these trials are not widely available, it is known that THCV has reached the clinical phase 2 stage for some indications[3].

Research Pipelines

There are a total of 256 drug development pipelines worldwide targeting the cannabinoid receptors, with approximately 119 projects at the non-research phase and 74 at the pre-clinical research stage. This indicates a robust interest in cannabinoids like THCV for therapeutic applications[3].

Market Projections

The market for minor cannabinoids, including THCV, is experiencing significant growth:

Market Size and Growth Rate

The U.S. minor cannabinoids market was estimated at USD 11.5 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 15.0% from 2024 to 2030, reaching USD 33.3 billion by 2030[2].

Dominance of THCV Segment

THCV dominated the U.S. minor cannabinoids market in 2023 with a revenue share of 25.9%. This dominance is attributed to the rising adoption of THCV for various medical applications, including metabolic disorders, arthritis, epilepsy, and neurological disorders[2][5].

Key Market Players

Several companies are actively involved in the development and distribution of THCV products. Key players include Mile High Labs International, Global Cannabinoids, GenCanna, CBD INC, and others. These companies are expanding their reach and product offerings to capitalize on the growing demand for minor cannabinoids[2][5].

Pharmacokinetics and Safety

Recent studies have provided insights into the pharmacokinetics of THCV:

Oral Administration

A study on the pharmacokinetics of Δ8-THCV after oral administration showed dose-linearity in the maximum concentration (Cmax) and area under the concentration-time curve (AUClast). However, the study also highlighted the potential conversion of Δ8-THCV to Δ9-THCV, which warrants further investigation[4].

Safety and Tolerability

While THCV is generally considered safe, the development of cannabinoid-based drugs is often hindered by adverse reactions and the potential for abuse. Ongoing research aims to mitigate these issues through the development of biased agonists and other novel drug development strategies[3].

Challenges and Future Directions

Despite the promising therapeutic potential of THCV, several challenges need to be addressed:

Adverse Reactions and Tolerance

The development of candidate drugs targeting the CB1 and CB2 receptors is often complicated by adverse reactions and rapid tolerance development. Researchers are exploring strategies such as biased signaling to differentiate therapeutic effects from adverse reactions[3].

Regulatory Framework

The regulatory landscape for cannabinoids is evolving. Clear guidelines and approvals are necessary for the widespread adoption of THCV and other minor cannabinoids in medical treatments.

Key Takeaways

  • Therapeutic Potential: THCV has a broad range of therapeutic applications, including metabolic disorders, neurological disorders, pain management, and more.
  • Market Dominance: THCV dominated the U.S. minor cannabinoids market in 2023 with a significant revenue share.
  • Development Status: THCV is in various stages of clinical development, with ongoing trials and research pipelines.
  • Pharmacokinetics: Recent studies have shown dose-linearity and highlighted the need for further investigation into the conversion of THCV isomers.
  • Challenges: Adverse reactions, tolerance, and regulatory issues need to be addressed for the successful development and market integration of THCV.

FAQs

What is Tetrahydrocannabivarin (THCV)?

THCV is a minor cannabinoid that acts as a CB1 and CB2 receptor antagonist, with potential therapeutic benefits in various medical conditions.

What are the primary therapeutic areas for THCV?

THCV is being explored for its benefits in metabolic disorders, neurological disorders, pain management, and other conditions.

What is the current market size and growth rate for THCV?

The U.S. minor cannabinoids market, dominated by THCV, was estimated at USD 11.5 billion in 2023 and is expected to grow at a CAGR of 15.0% from 2024 to 2030.

Who are the key players in the THCV market?

Key players include Mile High Labs International, Global Cannabinoids, GenCanna, CBD INC, and others.

What are the challenges in developing THCV as a therapeutic drug?

Challenges include adverse reactions, rapid tolerance development, and the need for clear regulatory guidelines.

How does THCV compare to other cannabinoids in terms of pharmacokinetics?

Recent studies on THCV have shown dose-linearity and highlighted the potential conversion of THCV isomers, which requires further investigation[4].

Sources

  1. Synapse: Tetrahydrocannabivarin - Drug Targets, Indications, Patents.
  2. Grand View Research: U.S. Minor Cannabinoids Market Size & Share Report, 2030.
  3. Synapse Blog: Progress in the Research and Development of Cannabinoid Receptor New Drugs.
  4. MDPI: Pharmacokinetics of Oral Cannabinoid Δ8-Tetrahydrocannabivarin and Its Main Metabolites in Healthy Participants.
  5. Research and Markets: U.S. Minor Cannabinoids Market Size & Forecast to 2030.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.